Seneca Center

Seneca Therapeutics is a clinical-stage biotechnology company focused on developing next-generation oncolytic virus therapies for the treatment of solid tumors. The company's core technology is based on the Seneca Valley Virus (SVV-001), a naturally occurring non-pathogenic virus that selectively infects and kills cancer cells expressing the ANTXR1 (TEM8) receptor. Seneca's lead candidate, SVV-001, is being evaluated in multiple clinical trials both as a standalone agent and in combination with immune checkpoint inhibitors to enhance anti-tumor immune responses. The company aims to leverage the unique properties of SVV to address high unmet needs in cancers such as neuroendocrine tumors and small cell lung cancer.